Literature DB >> 2959149

Tay-Sachs disease with hexosaminidase A: characterization of the defective enzyme in two patients.

J Bayleran1, P Hechtman, E Kolodny, M Kaback.   

Abstract

Cases of infantile Tay-Sachs disease (TSD) with high residual hexosaminidase A (Hex A) activity have recently been described. The clinical presentation of the disease in these patients is identical to that found among Ashkenazi-Jewish patients. Fibroblasts from two such TSD patients had Hex A activity comprising 16% of total Hex when measured by thermal fractionation and quantitation with 4-methylumbelliferyl-beta-D-N-acetylglucosamine (4MUG). Hydrolysis of 4-methylumbelliferyl-beta-D-N-acetylglucosamine-6-SO4 (4MUGS) by patient fibroblast extracts is catalyzed by an enzyme activity that comprises less than 1% of total Hex. Kinetic analysis of patient Hex A by using 4MUGS revealed Km's similar to that of control Hex A but Vmax's significantly different from that of the control enzyme. The inhibitors N-acetylglucosamine and N-acetylglucosamine-6-PO4 were used to distinguish between active sites associated with the two different subunits of Hex A. A beta-subunit site with little activity toward 4MUGS is sensitive to N-acetylglucosamine but resistant to N-acetylglucosamine-6-PO4. This site accounts for most of the hydrolysis of 4MUG. By contrast, an alpha-subunit site that is sensitive to N-acetylglucosamine-6-PO4 but resistant to N-acetylglucosamine accounts for almost all of the hydrolysis of 4MUGS. In mutant cells, this site retains the ability to bind substrate but is deficient in catalytic activity toward 4MUGS. The pH optima of patients' Hex A is shifted to a more acidic range, and the enzymes are significantly more thermostable than control Hex A. By using the thermal fractionation procedure for serum isozyme discrimination, one parent of each patient is unambiguously classified as heterozygous for the TSD gene whereas the other parent has test values in the grey zone. When parents are tested by use of 4MUGS, however, all four parents are classified as heterozygotes. Comparison of the results of both assay procedures allows the carrier of the atypical TSD allele to be recognized and identifies the probands as compound heterozygotes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959149      PMCID: PMC1684329     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  22 in total

1.  Studies on glucosaminidase. 4. The fluorimetric assay of N-acetyl-beta-glucosaminidase.

Authors:  D H LEABACK; P G WALKER
Journal:  Biochem J       Date:  1961-01       Impact factor: 3.857

2.  A new variant of type-AB GM2-gangliosidosis.

Authors:  S C Li; Y Hirabayashi; Y T Li
Journal:  Biochem Biophys Res Commun       Date:  1981-07-30       Impact factor: 3.575

3.  Chemical characterization and subunit structure of human N-acetylhexosaminidases A and B.

Authors:  B Geiger; R Arnon
Journal:  Biochemistry       Date:  1976-08-10       Impact factor: 3.162

4.  Synthesis of beta-hexosaminidase in cell-free translation and in intact fibroblasts: an insoluble precursor alpha chain in a rare form of Tay-Sachs disease.

Authors:  R L Proia; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

5.  Ganglioside GM2 N-acetyl-beta-D-galactosaminidase activity in cultured fibroblasts of late-infantile and adult GM2 gangliosidosis patients and of healthy probands with low hexosaminidase level.

Authors:  E Conzelmann; H J Kytzia; R Navon; K Sandhoff
Journal:  Am J Hum Genet       Date:  1983-09       Impact factor: 11.025

6.  The AB-variant of GM2-gangliosidosis. Clinical, biochemical, and pathological studies of two patients.

Authors:  J E Goldman; T Yamanaka; I Rapin; M Adachi; K Suzuki; K Suzuki
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

7.  Juvenile GM2 gangliosidosis (AMB variant): inability to activate hexosaminidase A by activator protein.

Authors:  K Inui; E E Grebner; L G Jackson; D A Wenger
Journal:  Am J Hum Genet       Date:  1983-07       Impact factor: 11.025

8.  Tay-Sachs disease: one-step assay of beta-N-acetylhexosaminidase in serum with a sulphated chromogenic substrate.

Authors:  W Fuchs; R Navon; M M Kaback; H Kresse
Journal:  Clin Chim Acta       Date:  1983-10-14       Impact factor: 3.786

9.  Genetic variants of Tay-Sachs disease: Tay-Sachs disease and Sandhoff's disease in French Canadians, juvenile Tay-Sachs disease in Lebanese Canadians, and a Tay-Sachs screening program in the French-Canadian population.

Authors:  E Andermann; C R Scriver; L S Wolfe; L Dansky; F Andermann
Journal:  Prog Clin Biol Res       Date:  1977

10.  Interaction of activating protein and surfactants with human liver hexosaminidase A and GM2 ganglioside.

Authors:  P Hechtman; Z Kachra
Journal:  Biochem J       Date:  1980-03-01       Impact factor: 3.857

View more
  6 in total

1.  Prevalence of different types of lysosomal storage diseases in Saudi Arabia.

Authors:  P T Ozand; G Gascon; A al Aqeel; G Roberts; M Dhalla; S B Subramanyam
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  More than one mutant allele causes infantile Tay-Sachs disease in French-Canadians.

Authors:  P Hechtman; F Kaplan; J Bayleran; B Boulay; E Andermann; M de Braekeleer; S Melançon; M Lambert; M Potier; R Gagné
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

3.  Pseudohypophosphatasia: aberrant localization and substrate specificity of alkaline phosphatase in cultured skin fibroblasts.

Authors:  K N Fedde; D E Cole; M P Whyte
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

4.  Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.

Authors:  M Joanne Lemieux; Brian L Mark; Maia M Cherney; Stephen G Withers; Don J Mahuran; Michael N G James
Journal:  J Mol Biol       Date:  2006-04-27       Impact factor: 5.469

5.  High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones.

Authors:  Michael B Tropak; Jan E Blanchard; Stephen G Withers; Eric D Brown; Don Mahuran
Journal:  Chem Biol       Date:  2007-02

6.  Searching for tryptase in the RBL-2H3 mast cell model: Preparation for comparative mast cell toxicology studies with zebrafish.

Authors:  Juyoung K Shim; Rachel H Kennedy; Lisa M Weatherly; Andrew V Abovian; Hina N Hashmi; Atefeh Rajaei; Julie A Gosse
Journal:  J Appl Toxicol       Date:  2018-10-30       Impact factor: 3.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.